985 / 1224
SBRT COMBINED WITH SORAFENIB
•
Phase I trial
•
Child-Pugh A cirrhosis
•
Not candidates for other standard local-regional treatments
•
Sorafenib 400mg/daily 12 weeks and after that full dose
•
SBRT 6 fractions (5-8.5Gy) weeks 2 and 3
•
16 evaluable patients
•
Dose limiting toxicity gastrointestinal 3-4 (bleed/obstruction)
•
Not recommended concurrent use SBRT-Sorafenib
Brade AM. Phase 1 Trial of Sorafenib and SBRT for HCC. IJROBP 2016